-----BEGIN PRIVACY-ENHANCED MESSAGE-----Proc-Type:
2001,MIC-CLEAROriginator-Name:
[email protected]:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQABMIC-Info:
RSA-MD5,RSA,
WujqXj/OBLqXyBeppCgAnWME6fuUF1y0s9AHbcmQ82grrOl0UE8lVBGdRdRznBqJ
aSjcYecL+fwUm84VJWxYnQ==
0000950153-05-000625.txt : 200503240000950153-05-000625.hdr.sgml
: 2005032420050324172454ACCESSION
NUMBER:0000950153-05-000625CONFORMED SUBMISSION TYPE:425PUBLIC
DOCUMENT COUNT:11FILED AS OF DATE:20050324DATE AS OF
CHANGE:20050324
SUBJECT COMPANY:
COMPANY DATA:COMPANY CONFORMED NAME:INAMED CORPCENTRAL INDEX
KEY:0000109831STANDARD INDUSTRIAL CLASSIFICATION:ORTHOPEDIC,
PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]IRS
NUMBER:590920629STATE OF INCORPORATION:DEFISCAL YEAR END:1231
FILING VALUES:FORM TYPE:425SEC ACT:1934 ActSEC FILE
NUMBER:001-09741FILM NUMBER:05702872
BUSINESS ADDRESS:STREET 1:5540 EKWILL STREETSTREET 2:SUITE
DCITY:SANTA BARBARASTATE:CAZIP:93111-2919BUSINESS
PHONE:8056925400
MAIL ADDRESS:STREET 1:5540 EKWILL STCITY:SANTA
BARBARASTATE:CAZIP:93111-2919
FORMER COMPANY:FORMER CONFORMED NAME:FIRST AMERICAN CORP
/FL/DATE OF NAME CHANGE:19860819
FILED BY:
COMPANY DATA:COMPANY CONFORMED NAME:MEDICIS PHARMACEUTICAL
CORPCENTRAL INDEX KEY:0000859368STANDARD INDUSTRIAL
CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS
NUMBER:521574808STATE OF INCORPORATION:DEFISCAL YEAR END:0630
FILING VALUES:FORM TYPE:425
BUSINESS ADDRESS:STREET 1:8125 NORTH HAYDEN
ROADCITY:SCOTTSDALESTATE:AZZIP:85258BUSINESS PHONE:2125992000
MAIL ADDRESS:STREET 1:8125 NORTH HAYDEN
ROADCITY:SCOTTSDALESTATE:AZZIP:85258
4251p70398me425.htm425
e425
Filed by Medicis Pharmaceutical Corporation Pursuant to
Rule425
under the Securities Act of 1933
and deemed filed pursuant to Rule14a-12
under the Securities Exchange Act of 1934
Subject Company: Inamed Corporation
Commission File No.1-9741
This filing relates to a proposed business combination (the
Merger) of MedicisPharmaceutical Corporation (Medicis) and Inamed
Corporation (Inamed) pursuant to the terms ofan Agreement and Plan
of Merger, dated as of March20, 2005 (the Merger Agreement), by and
amongMedicis, Inamed and Masterpiece Acquisition Corp., a
wholly-owned subsidiary of Medicis. The MergerAgreement is on file
with the Securities and Exchange Commission as an exhibit to the
CurrentReport on Form 8-K filed by Medicis on March21, 2005, and is
incorporated by reference into thisfiling.
The following is a presentation made to Inameds employees on
March24, 2005 regarding theMerger.
Our Aspirations
Partner of choice for our customers
Expanded product portfolio
Customer centric focus
Patient choice for enhancement of theiroverall health, beauty
and self-esteem
Innovative R&D pipeline
New, distinct culture, preserving valuesat the core of each
company's success
The Medicis Story
Founded 1988
IPO - April 1990
4 stock splits since 1996
NYSE - September 1998
Why the dermatology market?
Exceeds $5 billion
Driven by 3,200 dermatologists
Favorable demographics
Evolved with market to aestheticprocedures
Mission Statement
.. . . helping patients attain
a healthy and youthful
appearance and
self-image
Four-Part Growth Strategy
Core brand growth
Product development
Collaborative relationships
Strategic acquisitions
Stronger Growth-Oriented Company
Complementary products
Enhanced global presence
Approximately 1,500 employees
Operations in 12 countries
Business in over 60 countries
Enhanced R&D
World class customer service andbusiness support functions
Opportunities for advancementwithin a growing company
Integration Principles (1/2)
Our people are our greatest asset
Maintain performance and customerrelationships
Exercise fiscal responsibility
Build best new business model
Integration to maximize value
Joint task forces to address integrationissues
Great talent from every part of theorganization needed to
maximizeopportunities
Move quickly to operate as one businesson day merger occurs:
One management team
One operating plan
Business as usual until then
Integration Principles (2/2)
Closing Remarks
FORWARD-LOOKING STATEMENTS
This document contains forward-looking statements within the
meaning of the SecuritiesLitigation Reform Act. All statements
included herein that address activities, events ordevelopments that
Medicis and Inamed expect, believe or anticipate will or may occur
in the futureare forward-looking statements, including the expected
benefits of the merger of the two companies,the financial
performance of the combined company, the year in which the
transaction is expected tobe accretive, and the anticipated closing
date of the merger. These statements are based oncertain
assumptions made by Medicis and Inamed based on their experience
and perception ofhistorical trends, current conditions, expected
future developments and other factors they believeare appropriate
in the circumstances. Such statements are subject to a number of
assumptions,risks and uncertainties, many of which are beyond the
control of Medicis and Inamed. Any suchprojections or statements
include the current views of Medicis and Inamed with respect to
futureevents and financial performance. No assurances can be given,
however, that these events willoccur or that such results will be
achieved. There are a number of important factors that couldcause
actual results to differ materially from those projected, including
the anticipated size ofthe markets for the companies products; the
availability of product supply; the receipt ofrequired regulatory
approvals for the transaction (including the approval of antitrust
authoritiesnecessary to complete the merger); the ability to
realize the anticipated synergies and benefits ofthe merger; the
ability to timely and cost-effectively integrate Inamed into
Medicis operations;access to available and feasible financing
(including financing for the merger) on a timely basis;the risks
and uncertainties normally incident to the pharmaceutical and
medical device industries;dependence on sales of key
products; the uncertainty of future financial results and
fluctuations in operating results;dependence on Medicis strategy
including the uncertainty of license payments and/or other
paymentsdue from third parties; the timing and success of new
product development by Medicis, Inamed orthird parties; competitive
product introductions; the risks of pending or future litigation;
andother risks described from time to time in Medicis and Inameds
Securities and Exchange Commissionfilings including their Annual
Reports on Form 10-K for the year ended June30, 2004 and
December31, 2004, respectively. Medicis and Inamed disclaim any
intent or obligation to update anyforward-looking statements
contained herein, which speak as of the date hereof.
Additional Information about the Merger and Where to Find
It
In connection with the merger, Medicis and Inamed intend to file
relevant materials with theSEC, including a registration statement
on Form S-4 that will contain a prospectus and a jointproxy
statement. INVESTORS AND SECURITY HOLDERS OF MEDICIS AND INAMED ARE
URGED TO READ THESE,WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT MEDICIS, INAMEDAND THE MERGER.
The proxy statement, prospectus and other relevant materials (when
they becomeavailable), and any other documents filed by Medicis or
Inamed with the SEC, may be obtained freeof charge at the SECs web
site at www.sec.gov. In addition, investors and security holders
mayobtain free copies of the documents filed with the SEC by
Medicis by directing a written requestto: Medicis, 8125 North
Hayden Road, Scottsdale, AZ, 85258, Attention: Investor Relations,
orInamed, 5540 Ekwill Street, Santa Barbara, California, 93111,
Attention: Investor Relations.Investors and security holders are
urged to read the proxy statement, prospectus and the otherrelevant
materials when they become available before making any voting or
investment decision withrespect to the merger.
Medicis, Inamed and their respective executive officers and
directors may be deemed to beparticipants in the solicitation of
proxies from the stockholders of Medicis and Inamed inconnection
with the merger. Information about those executive officers and
directors of Medicisand their ownership of Medicis common stock is
set forth in the proxy statement for Medicis 2004Annual Meeting of
Stockholders, which was filed with the SEC on October21, 2004.
Informationabout the executive officers and directors of Inamed and
their ownership of Inameds common stockis set forth in the proxy
statement for Inameds 2004 Annual Meeting of Stockholders, which
wasfiled with the SEC on April29, 2004. Investors and security
holders may obtain additionalinformation regarding the direct and
indirect interests of Medicis, Inamed and their respectiveexecutive
officers and directors in the merger by reading the proxy statement
and prospectusregarding the merger when it becomes available.
This communication shall not constitute an offer to sell or the
solicitation of an offer tosell or the solicitation of an offer to
buy any securities, nor shall there be any sale ofsecurities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior toregistration or qualification under the securities
laws of any such jurisdiction. No offering ofsecurities shall be
made except by means of a prospectus meeting the requirements of
Section10 ofthe Securities Act of 1933, as amended.
GRAPHIC2p70398mp70398z0001.gifGRAPHIC
begin 644
p70398mp70398z0001.gifM1TE&.#=AT`(M4K644K7>&;64&;7FWFOFE&L98R$9O2%KE,5KWM9[UD)*UD)[UA!*UA![O81*MO82U$"&MC&OO4G-*YM;O4B'O&7-K2B%[C!D9C&-*C!D9O6/F[RD`"!#6C#JMME)RMWFOFWISFE)P9E"$9[R$90CI[[X1*[X0I4JT9[V.MUIQ:(>9:(;4A8ZU"M2AE"2DH9:^80*4(Z*=8A*4H90M92A-8Z6I090H1",909&3$9(4)24MY2A+40M*7,Z8Y1"4I1*:\YKA.\Q6HPA4HP((3$08Y090HP(*5HI.FM*C,Y*-;">A`HP!""DD77&2":6:89Z99II!YL0E'7F\*\.:!^MVVU$XW*K[;D&IJONM-49I-Z`$^UGSPKV1%1OO0S@2U&\&@6!T((,1G22P"9%M5))'`YLD$DL10A[A"RA-+"'C];(D[%!"'B_!`NRVR)]Y,H>XQ#M*5$)3J0BD_D$*@",RHA*I[/4`1!G$'S@C:Q4)!N1#E@W^TJ,>I2ZL5BI5TZ+MT:_HLJ4DN6@NBSO5JNJ2I+J4*4V6$L`=]A(FK=E)4()JVZ#"!@RQ]>9JU2V$XWHK`!!"OKJ]A_"+JUX-*T?PI2];\LM\MB&V0,A7BE/.`0A$-_/0W?IFHA+M6D4O4IR+)/>A#_])SD8]VA&.>+G+M8)HFF-=54A;)E:2R.O$@6$YAWK3*UPKHU&Y7=*(NM;EW&G8^IG/F0XKWE68MZA0&WJ-DZ4M=ZCXVT5TL,YGTY3(=H`;$F='AW40A#[email protected]%_P&&2KBAM`"XH0V'*X)5*.$'W_SWJHSX,,(`$Q2GIL`46%C]\@F'N)#_U0R>M$F(X@1,4M(5\QI3NULT##8G(BP6+#XE&$_[$!=;1IXB$VXS$T^(`(K'$RRS!;FB4WH$1[$H`AM$L(A*.(AM12)-N,."V[=N'I@4+,9-W&08)3%^&__!4BVA`$[#6'JD'9=DF,EQ-M^'O!A2*M@VXR//)3FSJ2*XME"/!!%?5M45L9SK%1#K*V%W)=#IE870XA2TN^$TN45Y&$4WCUW(:B!$`[0T?*E'U&$=MEM4=:HI9C]B(:8-JK!>5H@9)CZ@A_[$>JX8VH$>8/>`?$@`.8L5G`@`-C1A*MI^@@JA0BJT0A@\,WJM2*M'@BK+0AK:@XK$0C)?(X,6(CR`>,EO,CJ>%+6A1]M;,5Y%MV;8D/X5F#%,FXX6-X(02YZ!>*(F2VE(FMYHKO4-S:F).%D%O?9(.$#/!F70GM`*QE'IP!#7U(2)F)#YBI'):9-[=U'J67X_(3QQB(-#M.F=?>*IOQT4EX!4%\B;`9#F^M`AU299;,`S!(`9_9QMDXA$%3=IHE70V7-L=95,V(H"3M!RH.L=F)Q>2)/!:8]T%HHDQ)0TRHIZ)D^D9*M`!EQ\-,I!\4G&,=0#@6!MQFN\(!81#:&NZ]J\)V87$A%2](J1V9NK]RK+(G$2VRM-1]&NU0E-NA,2SSE>MJ]-!7T>P5^&2VE`!:5`O%6N550E6-Q08JCJ31K>BB(:$3Z@Z2DDF17F72?^TM%S&(&$D9LC-$.E"Y1!1CE=.7%9_AA=$'LQISI*?!%^YA5UO@9&@9C(2EMH"AM`8!&"G0("W7`"+\A`5O3@PC":%`SMI3W1]*QEY/U6$[S:&^*F#U,'JS7-4ZEM`S?\`14P#'?0MNEA-85TF7ETMNF1MF'!`(N&'_.!-?T1'K,&''Y3T,#1J).*MT[S'-WE;BXVSJT1-S19QX15AH;]=U;\7NPQ(Y4)4"'9EAF8AVS9;H&A:2*0.MG#$1?$77Q12EP"%0`&M>P4J4:_M/>W10@F$L@PA@0@X4X%"!O,4#M`-5X0M[L5RD%1,,YM4&/T?!@.%+,H0[EH-.;KE%#&F8J9XDLM*5R5`!(@PLG#E2D3#JI2*T6,&68N?7D5&6U-,0T84+,7M@Z#5AOL=.%B2D:.!&6K9IAK3O`]``WZ+L!Q$CN=P-%BRD">P)V@@L$6X@QLTL=MXI0J(@B>(@@J``RC$MKAH(A@IX''+ZG2I!*.=I.22!)WA:$^F)L:BKD.ZI$/>2$R#S,0IQG$09E*GSM*'G`PT,QLD6)AD@1E`%1LO@!`$QIJ4YYLE`Z#5'YGRK[K'BSC(K8+)X2B%$0%(MJ0`9?(]58TJFC()7BH*MV\.;',/(X,#WKT7?HPM-FG[C;/I@J`Q7@G]#=5P4'6U3NW$UPKHCDX.0%".9-4M5U,VY;4YFVIXC0OEME`K54+:#C;Q)S,(T.UN&%/%=K_^^5!^)PA,[email protected]+;56FM2##X#:073A0FSHK6&)M4>7$_]`;^&P8N2U%L[B7[G4NSW?0C5I8(0+0_W/7;0BGD;0M?W68^('4^`T,2*TF9!B,?V$8;'`828$8^15,PQQJ:RQ,MD",;:@8;MP$Y8`21VR8>P!NO4B*/048]A=1V#>(U"VJ";Q5N[=;`!HI3OJA4]A*A-*R_QE9!?.5!MY"'P9.B/3@G!%N6H]2J15O+>VD_NG:/D\M_ER6SEDBKCB#D$L]N=P3L%?FFA-RG)1(M\EP?W131'[32OM$T``,%"!8,$*&@H:T"!`P$*),(,`#'P#F)!C!>/#B08P4#`CT"\/A$(,D*M`$22)+D()46>9[\^60+ER=(/0/ON(7QXY_*`HK=>1'WWMZC@G6X\LQ4TPZ&I>R/2V,CFIO4UMBP9:3W::H[LJ.LB/PP$DA99Y2$`EQNML]S;KL;W68T6DW.24X\\I%PA:0XUW[ZM9XKT^,G2BK'3@?FDG8`(>1KK.K(K^1+NU`:I"P>':V+6JU\?(FR>/XB[^[.D4M\4JO`ETPR#D2(BJ'1$0`UW-O?(L/WXZ(C[PA,3\PA5(@T;#4F%S0_###L7@14M\4>=%MY>(+'0P'^P(QFJ7%8,PQ`"9@Q`A1L`9AN$IA/&.&=L/'4(,V6(,V6D,:4F-%M(->;(/?^[-G_!'WGREW9:-^CA(O_#B5O_*I5L$MCAG+XM\L*N+2HBK0Y232I=_6Y>%&;##4XACEA=^JX?]6PL0\SEY(R%]$;JYPM"FDL@^B@"&5&AH96KN56@^8>9JGX!!]NJ#5LSJE`)CAVCN=B:#-*-C,FU`TLSF\M)&RBV$]Q,@21(`L+M>:T+-6LHEPL1&ZV2_]K`3NADDY02#>$DUD(IN!@'+"5'U,CD,4@U^HR83_1NZ-:(;84.XX?B-O(_`>M8XX&\FX#*L9O?^C(^O'FOE,TAB,$RU-E%.9`B`/H7B@SFJ@[email protected]*G`X\MXK,ZXG,[;+#I)-'8TL/&[,.,X&Q`U(SD[,AIK%4]W&S,FI0\P@8:_JB*/"!"M`0F0!FF9='*0*)0GV89V.&L+F2M&@K)$ADE([48,;V23>N2TWN3P=J0LI1*XMFL1SAJ1,R$0.-Z?R6,E[)2]\MX1A:[1T;NE$0MW$@I])&75)%G%SN>YF2/ARH=HM$IU4ME,@+RV=!R6MN?(.5Q25NN2O593(W=!TRG+X0=3O+E:8A]0M;T>1LIK7I4OM@J)9MNGRSL\4@I`TDQGR;M_E4*.(AV,M4O&=,U_S]T4(6`0)`!0`$`3P!H,#@@2=/M%#Q9]&3A@6@1(1Y8I"#:@0,9.4[>5)("_!S641$D2X9_^^_0;W\^>W$3'_\+P>M(MHX/MQ_\!^B=@#S,8V`8-/B38Q@P-+CB##S-$.$,],[P080=MO(`AAR]TMD,,+/H3H@XV.#6##H888-MM)'GA#!TDB2'::),F*]J=(QUXWVBCWG>SJ"*0/YKX#]MMMF]C!AR]8V.2!$';-8(%7)T:YP%/GY1!QR$+"PJORP>0HY)-63Y)2MK'L:)5A;L6=2IN5/^Y%+H%7ABD'JU*NL',1;+M$?62F'#S)&)99SK98LYT/@\YM&$D)JC)2D>1UR6+RH(>597T/6;-$G[1*C:W[Z0_EM=K`?_R1F/W'4VH$ZTC5L#NJ0@_38(.;I@VRDZB;ZS,RKSLY@I'YQ!'YQ@'M2E'3IJSD%3QJ+Q`@E2Z$.QYL45B=H]-RS@SI+/Z2_`0%HT[,#R7/RI&5M2D*M8"(EU.KX\+:6-.3S/Y]4FJ/QJ(76!I>;GH(-BU`)\>*(V45QA8O_[_:.M"JD)('0\>-#N@4"!`Q,.+/@@0,$``R%"'/"`XH!Q%0=HO+AQ@#B-XSQZ^&C-MPSB3(U>@C")N),J3*#_*O!C@8\@!'@)T'*!3)T^-/7_Z#."39\^C0'/RS-F3M:8!Q1(TR98H(9]2C4P/DS"D@0%>N6L,*$&!NJ]:J'@2(JUDS[=J/)@5X,+>NM94L/*%SF;8E"7-UU+%``?K&N`@H6_%A46+Q8,>,4C1E7@%P!V&++BRDS5LPYM1(41%3QSKJ"X,(H1IT(!!UZ1M?CWO=2/8V^;]F44(^ZE=LW`]0O%]T@`6LYB`D!4X&3"0D3,9.2F0`P*#&*00M(0!>K2%NC*)7QWM49:R_&(.OE@K6M::P;/4B1B^*+-2/VEF,.5AF6#>#YGZ@U3_FA#XT'NS`$#P99LUU3AD>\`0J=!U+SW924T19PO_,7:N%4!=ASE)N'E+9VMATHYAWPH>N!C%]CE7:W7>NO$&-$B#WPQ3][2&(]!:LAD*9_2AIU&^=,C#9DMZ5&.-N.8SS0,,8X!3V'.PZR\\,5C]\_V!%^`'0"TJD'_T42&4$M"A&"&M0@"N$,0CTSD,T,9*&8U>QE/@,1A>"!10.]3$3PP(811:8T&,6'+_"9MVHW&HX+`L&4M]*/-C^8X0MY(Q#E+.I*2FC22)ODQ2B/(4B#ML:639,E,8NK2ME_16N"GA#7'&:.3A``"FN$WJ32@1G4#FM$8(M2D(0.D;>6F==`N`$;5)EWUA9>\31>"5-;R#I[LM%/L879$J=Z9(/5S08!T$B'0N=?2;L.>Y-M*'WIJT,$V\>CHX^/S^=SG\A4)C(C([QW;/_OT/[X28S?$,`)PA*)W'A2C0^OA421T0Z!AM*#)`3.8SY(8]#+P&WM&@6H8N.P(@(((RO&(B#PDO0``#[B(S>V8T/&8^G71D'&(FQ#9!60A1(A!TX%FM++"(Z^41SS&CSL&5E0HQ5KJ3%`.)T:%J'W5#1*@-ZJ%[D?%"+M2)3:H1+7I"M_QWE,I.89M$1!6=V9@JR(!5R1)5421V6B^/2+Y#TJ$DC`@SX;PEH:RD@$"OWM-(3S?2EB?C5BB%T2FA#78VU31M(H1T[U?F]JM!E79&"5"&EG4)3MFQ'*9QHJ9AB/EF+K:F&[EF2(@C0"_7&O^S9BXP]8=)HC2.1$4E660TT/?)+B0H71H`GYHML42,`$\/+Q,M`F"(:N%HU+/%MAZL[(`,$2YZJ_6X_H`,&T[47"&?Q&[L%&XL>>T/U@,`U@.%MAOCL_WFZR`7E8(T2&ZD/R"78+YKMY5JOGJD.%[(:9\ZA*:#81%,T&^D:7ZT.M,*`.^X#6OX$03*1$Y2YZ7D`/]_!`M"B?E/WM&)37+;KBQ";>GG'(D[T?4QY#M'J#8DST`__=`A%6-RT2X+1%+A`P?&=&.:4"*I-S>\:+'V6]`0BM@[S8.+O&M@7Z/(`M@YU^>R(J1^U^>PO'R=L&$DZOMWF+4+X1P^MG0Y+X2PFM)NO(*V^J([`6@:FW6:DOJ@PX2=(2A?0Z:H80.3@LI3M?R+"T"\KY"NS"!-ZM+B4F]`Y)#;A0XUEK--*:\CBFOT037N%HC6S0)QV`&;2;\M.?_,#QK?V!!C/JM`F=D_G?K\@Y0G?K:%Z&\FILQ+;"X^..&3$N$3*A,(ZAF+%-`&@V">[K@WM7`FL3!H(-7.4CG`S..LD.P.*31D)4AG!GTC!4P*M3QF*4E$E0!.5=J`SU>M6!%,H7.^S7AX+$Y]6'AI%1M[."8%H*@3,Q>?7-K!AT8)B5:LZF0=CJ"4H$"=5V)BMO4VE*>:=*8YOSRK5+)8)J1BTI%!56O)AXF$MZ:.`CXS/2!NB,ZYFEG0++MTTM[=F+O#.K#0XV8LUJ\SE0T/5\"L$"M=4/@SV-*WTAWV8>7U*@\+8PO#-+JLJ>*AB)0"299*5V%Y[L94H)R$+C6:1C">ID!..,%``JCH^;.(-C3QH(A#MOD0A0[2'11IS`-/^Y!`0"0G=TEUM:,KT*(&8Y"54RJ.:Z,9"6G8O5N4"T=W0A2MSGBME&J`FYKG&,6"CE\R:F@6LD+:.CF:*I)I5&[(0!X7SK)VF:TA&4E(VN22SWU$M)7"RE*,ZB9+5#7TFHNF)U430MMC-SC-V1E*WA'IG3TLF5;RKBF4G*SRW^"JSMS%/+H,>.EN*5]NS`(J9GS_Y+M\,=,/]X^:5K>Z[DWOA^Z_>G>/%;M/")7UD#)J8XC;G&*HGG,[[=O@`(--@Y[:&^RNTY_44?7RT$..(+3^81A/H+[MZ8\%369?_]57G.!Y[WS7\YZ-(,&&R0,_YC50OPA`=GT7KOG+Y4$4?M7'MO"Q-=,&+ZL67;&R0NY2'0;S'/XW'!YT,14$(\MW>@0"?MN4>N"V?@;00@M1>M@TC;S2B(A5#(A#44A3F86TY?OJW4]'E?]_]%X`/:E(RX#0NDV/T!I"G5F0S:M&3`NG!CM`U((!4\)9F3NGS3B%%X!X%\:X%\6F>@`YB4!3CP"&26Y8P(22AV%M`Z$8RI7522(E$M.$$Z%$6:#,CVNFVD",1)S0$9IU4J-H4DS8!)N1B^&QA-;$MCF'%66)*TPSF3NY4Q??DH%9@H9_](*P@CZ_HDA`B6M@9VJ\0&F%P)S"Y';$$MAO;P2O!\Y!0NAA3ZCK6T2@I4A=_Y2&)RRQ@%)ZD%)U=-TI;5G)ZLAY^XBSE-MEP0!T`-EGG;-87`8Q^?AX3TE!WF99;')WG>\VIU\3!)U#&ND"5M)J]J7B+=*5N4:?0`3]I..BLYK;_SK@%68ANK+(N4IL+SP9[W'L,JH#66J#MG"4)[BUFD:B`N,D?66KLV,SK4-RK_#WF4EV-Q)+E^^$K`JZ9`C[COYYLF;)1MROKL@&V)FD!LEZI#ON[76'G`OY)L:'K`T_9"",SK@'6I.DHM[EUMYPA$_'4IMU^*>V69@U3YM1MC4E/RK2>0$F;`1`K;$'*D.4/^TX'#R;4\8IPA4T\(EIJDTM5D$NIZ:RBJMTCUA,9Z@F3V%`)/,@VML=(6/,!=F]:JXTH6RU'=TY8:QN+F+HMQ=PI!F-DX6UQQ50`UPPVQ7QVRYNM3W#&Q"3-Y@=NV;ZE'JQMQ[5%0K.JTW,@M9;3J('CT``"9"XKVN*/BB;UC*&RC2[P#`;_GZ$"OJT/W&MKTSU@OKV;\"%`[K=JY8&7\451?@B!:6B6V/^+P``L#]20/P>\-D4#@Y*,*4,/JO$31Y2TV`47A"05H0"HI?6'@M+98T7:I[6LNJ4,NKF`78.>2MK$5:6"=:Q`5=Q!82@I;:-9KU!$9X&LMJG2=>M*!KI(I/I3I;>,N#[[%6(S6H3D/9X$6HU7`6\R%MVQ&3'&]DK`Z+;"WAK!H&;@F&'K-*[S`&93A%*C$%"YC*,$1Q?8Z+)FD3;](DMZ&@9[OYG.7T,4TKR`=U+\49'@$R'/24O/@D'"3&K4S:4Q33;AF8,M58('>.`R:Y1#^+KE)0H,6W.B#@0?,NC#)XZO+-,#,O^P@US?J^_I\HK>JUSKM0">&YPE2>.AH+5?PV%1K!C1YVN11"&\HJ2VE304R`O-D?P6RLJJ)FSE2HL0@$M8T%;;,#!DSQ:1!5RS!P48@=C?`]\1+=\F\977+4M:0FYBR(:7$:$("[0BT9XMW)1$R*B.K,S*%WT/W[!$#0DZ+#NYT%*@Z1&-V-VRO$LJ[_JEJ_L_M)JTS_]UZ#S5T#X24Q0&YBP!BH_C2%'',H]KCV_=8L@+RU5FI2,4KKMESD4()M)*60(K@[L8T$B\TQ`H6@6:S:CQTQ@:"/6M$D@(TCMU"()0M7\#KB:_@QAL,&P;+U2W)B$PA,,J;$QY1(-14LL:CP73#76;S$S&DJ;NIO"!QME(]DO;3"D1I!0I4PD+9`J$HYQ=E#J%Z-BUL=1R>SO;B0EDEE'\]*F,4EOCXTMEL,REC[4N/J`86A%RMQ`1)ODN((!C+9^I8XD:\`9MCQ.2XI4B)M1=E]T0&.#M2(#`7*1.'*U2DN%N3]2EWL;F+$LDV$KN'-.BD[UO_\D0ME_,=@MY,_E?9")9A^+V9C^8E*C(&ISJ,#'>>GN0",3_E^XDPFY"Y+(XV512;'IQ+`PM8=^F!N%1+QF2R[9(_Q5]Y5%^E%=2'`"++H^L+:VM*#:)+7^GNM52$XTFI7M,5=W$5RM(O**YE7)$ALA$B8@$;GU8H8L6NCP*U*2:NU"-)XL/-:ME6N$,E8'4I"-?J>"9I]M(AX5SSY)TDED@>%NUDD_O&'66-!#B@\8OG&/\W$7M+J72BIXB+_>H5,2*,S]QF8Z(0Z5\E931`-C8]@S]2VU^B4?VLQ5\$$?V*_M+$N`1PZX'`Q)`^.OJ#.7?1BYR7R094ANTM%C.5[KMF"'F0#:AEY5K5U;N7VL;,HGNN%%ECG"2IPG:BAC?$XR2H`5:H.W3%/P92*#DMKNZ)3I824\ZHF(>(^MWT'&J("J?J7"-"CL#NJLU9`9>BLS'TJ9?ZLSDBY22:M9OS>RK.B/!%-K;5ND7&`O0U!_/S"M3#!6>7PU"1/TTMA`_(8:180:]8/(@Z/M-_.,R%UK&-#__^@KM)3?!SUK/[!?6L7,98O'(EL%33F5)29C2>Z8SNP&49RJM*M9:6D4SAZ9(49S6C[X'.3_$4I-N`)2\+6(RE"0L8Q>D&D(2OIJDXAQE.N"DPEM]?^B&+28@#"2,Z3^X%.J$)35YS=4K5T-6M9\D,78/U*]2X=7>WXLVAM;FE89RV'K_@0"+;BH:UME98@,P%LO:9CU/%VCICEFG)#O".YH_3+7V4Q`3;/M%(]K=,6:D%L6MKS%KY?0C&(WN>^1#CS>(8B$)VVNZ4*T!)$%E2TD6*+9U:!FM(83&3(8!H)F'2$CB#(##4WGC$$#;58##5+0CZ2W.3CS_E3FFHT_QESTNM!#B88SX.#IN,#!CJHSEUQ$?P&4@"89U$7L]!GCZ"&5J"&1C*(ULJ#NB!MQWB4Q_M\V4N8`^M$6"(.$O!16.MPE:M4XC!>%;9IVR'UA6,\4B/MGHFABHG%MBF.R2O+AF"DAGZ^4(HZ1$KB4HKVU_R*/5-]@"29?A9@U:@HDHB-@MM0HZGF-B+*)6Z,NS/)4`/M4V2=,W8L5ZL,7I"6!3U>;^X0M:ZF8B-@!71+=B343=UX7B2)M=``)A4`'5"2*Y*"'=,`+>I!\QJ=X%I=\:I"%I$C5[0O51`U^:HB@F2!/$%7[$.]0S$99D%KME/YDA;_'B9P$357*+>A)&C;C[8XS!*HH!>MH.RI/MZ,U+W@>J9G.%QDM.,CG?%)JAV3JUE%=?8HG2HI0S,","6I)DISJ&FV$YD&K3>G7'-I'M@P4GBO)F88Q67BHB7UX*)'+58'(8EJY%B@$&N4U5ZF@%*,E*663_529&9BO]M#BRNHBGB6(_16+[.:^\PWV]+LMD67AJF7UL[GV`4S7LMZ,@[email protected]=0BNOW52%#F3B7:46M":1"7)'-+FK/FJ"%9`@*8DB+S.>DFJ>H5J1ZW@Q\*AK2&E0(;&K5`I1'^N_7MO6]']F_0HIV/"%=^9M!.-IW/SBIWNJU\Y1:O1@2P3K!NH8Q4WJK/;4E3$"M6M]MS>?.48[4E1N$2T,NOW[HG@OL2(;H2T($K"J.QN>AQQ\A^U*2(.;RY6H0Y2SZ)[`Z"55HB?>>7&:D9P]IRVOMMO%:?M#^[E=CW?=Z[_=_=WU]C_W9=_T;+W(&)9R!3*;L$1$C@5K:X7+K`C_PU^/3(3ZN]+%..ZHCTBB>(ZESEMQ9S:[M\9MB5+:,04V()NK!0D,71@6P'YDQSI+FZQRGD:>2XKG/Y^$VM88R0#XC&VS9$MM?O"S'M7:40)*!(S/BE$-M_3#HD!(:I8,D-*$*>0A$-_/0W?IFHA+M6D4O4IR+)/>A#_])SD8]VA&.>+G+M8)HFF-=54A;)E:2R.O$@6$YAWK3*UPKHU&Y7=*(NM;EW&G8^IG/F0XKWE68MZA0&WJ-DZ4M=ZCXVT5TL,YGTY3(=H`;$F='AW40A#[email protected]%_P&&2KBAM`"XH0V'*X)5*.$'W_SWJHSX,,(`$Q2GIL`46%C]\@F'N)#_U0R>M$F(X@1,4M(5\QI3NULT##8G(BP6+#XE&$_[$!=;1IXB$VXS$T^(`(K'$RRS!;FB4WH$1[$H`AM$L(A*.(AM12)-N,."V[=N'I@4+,9-W&08)3%^&__!4BVA`$[#6'JD'9=DF,EQ-M^'O!A2*M@VXR//)3FSJ2*XME"/!!%?5M45L9SK%1#K*V%W)=#IE870XA2TN^$TN45Y&$4WCUW(:B!$`[0T?*E'U&$=MEM4=:HI9C]B(:8-JK!>5H@9)CZ@A_[$>JX8VH$>8/>`?$@`.8L5G`@`-C1A*MI^@@JA0BJT0A@\,WJM2*M'@BK+0AK:@XK$0C)?(X,6(CR`>,EO,CJ>%+6A1]M;,5Y%MV;8D/X5F#%,FXX6-X(02YZ!>*(F2VE(FMYHKO4-S:F).%D%O?9(.$#/!F70GM`*QE'IP!#7U(2)F)#YBI'):9-[=U'J67X_(3QQB(-#M.F=?>*IOQT4EX!4%\B;`9#F^M`AU299;,`S!(`9_9QMDXA$%3=IHE70V7-L=95,V(H"3M!RH.L=F)Q>2)/!:8]T%HHDQ)0TRHIZ)D^D9*M`!EQ\-,I!\4G&,=0#@6!MQFN\(!81#:&NZ]J\)V87$A%2](J1V9NK]RK+(G$2VRM-1]&NU0E-NA,2SSE>MJ]-!7T>P5^&2VE`!:5`O%6N550E6-Q08JCJ31K>BB(:$3Z@Z2DDF17F72?^TM%S&(&$D9LC-$.E"Y1!1CE=.7%9_AA=$'LQISI*?!%^YA5UO@9&@9C(2EMH"AM`8!&"G0("W7`"+\A`5O3@PC":%`SMI3W1]*QEY/U6$[S:&^*F#U,'JS7-4ZEM`S?\`14P#'?0MNEA-85TF7ETMNF1MF'!`(N&'_.!-?T1'K,&''Y3T,#1J).*MT[S'-WE;BXVSJT1-S19QX15AH;]=U;\7NPQ(Y4)4"'9EAF8AVS9;H&A:2*0.MG#$1?$77Q12EP"%0`&M>P4J4:_M/>W10@F$L@PA@0@X4X%"!O,4#M`-5X0M[L5RD%1,,YM4&/T?!@.%+,H0[EH-.;KE%#&F8J9XDLM*5R5`!(@PLG#E2D3#JI2*T6,&68N?7D5&6U-,0T84+,7M@Z#5AOL=.%B2D:.!&6K9IAK3O`]``WZ+L!Q$CN=P-%BRD">P)V@@L$6X@QLTL=MXI0J(@B>(@@J``RC$MKAH(A@IX''+ZG2I!*.=I.22!)WA:$^F)L:BKD.ZI$/>2$R#S,0IQG$09E*GSM*'G`PT,QLD6)AD@1E`%1LO@!`$QIJ4YYLE`Z#5'YGRK[K'BSC(K8+)X2B%$0%(MJ0`9?(]58TJFC()7BH*MV\.;',/(X,#WKT7?HPM-FG[C;/I@J`Q7@G]#=5P4'6U3NW$UPKHCDX.0%".9-4M5U,VY;4YFVIXC0OEME`K54+:#C;Q)S,(T.UN&%/%=K_^^5!^)PA,[email protected]+;56FM2##X#:073A0FSHK6&)M4>7$_]`;^&P8N2U%L[B7[G4NSW?0C5I8(0+0_W/7;0BGD;0M?W68^('4^`T,2*TF9!B,?V$8;'`828$8^15,PQQJ:RQ,MD",;:@8;MP$Y8`21VR8>P!NO4B*/048]A=1V#>(U"VJ";Q5N[=;`!HI3OJA4]A*A-*R_QE9!?.5!MY"'P9.B/3@G!%N6H]2J15O+>VD_NG:/D\M_ER6SEDBKCB#D$L]N=P3L%?FFA-RG)1(M\EP?W131'[32OM$T``,%"!8,$*&@H:T"!`P$*),(,`#'P#F)!C!>/#B08P4#`CT"\/A$(,D*M`$22)+D()46>9[\^60+ER=(/0/ON(7QXY_*`HK=>1'WWMZC@G6X\LQ4TPZ&I>R/2V,CFIO4UMBP9:3W::H[LJ.LB/PP$DA99Y2$`EQNML]S;KL;W68T6DW.24X\\I%PA:0XUW[ZM9XKT^,G2BK'3@?FDG8`(>1KK.K(K^1+NU`:I"P>':V+6JU\?(FR>/XB[^[.D4M\4JO`ETPR#D2(BJ'1$0`UW-O?(L/WXZ(C[PA,3\PA5(@T;#4F%S0_###L7@14M\4>=%MY>(+'0P'^P(QFJ7%8,PQ`"9@Q`A1L`9AN$IA/&.&=L/'4(,V6(,V6D,:4F-%M(->;(/?^[-G_!'WGREW9:-^CA(O_#B5O_*I5L$MCAG+XM\L*N+2HBK0Y232I=_6Y>%&;##4XACEA=^JX?]6PL0\SEY(R%]$;JYPM"FDL@^B@"&5&AH96KN56@^8>9JGX!!]NJ#5LSJE`)CAVCN=B:#-*-C,FU`TLSF\M)&RBV$]Q,@21(`L+M>:T+-6LHEPL1&ZV2_]K`3NADDY02#>$DUD(IN!@'+"5'U,CD,4@U^HR83_1NZ-:(;84.XX?B-O(_`>M8XX&\FX#*L9O?^C(^O'FOE,TAB,$RU-E%.9`B`/H7B@SFJ@[email protected]*G`X\MXK,ZXG,[;+#I)-'8TL/&[,.,X&Q`U(SD[,AIK%4]W&S,FI0\P@8:_JB*/"!"M`0F0!FF9='*0*)0GV89V.&L+F2M&@K)$ADE([48,;V23>N2TWN3P=J0LI1*XMFL1SAJ1,R$0.-Z?R6,E[)2]\MX1A:[1T;NE$0MW$@I])&75)%G%SN>YF2/ARH=HM$IU4ME,@+RV=!R6MN?(.5Q25NN2O593(W=!TRG+X0=3O+E:8A]0M;T>1LIK7I4OM@J)9MNGRSL\4@I`TDQGR;M_E4*.(AV,M4O&=,U_S]T4(6`0)`!0`$`3P!H,#@@2=/M%#Q9]&3A@6@1(1Y8I"#:@0,9.4[>5)("_!S641$D2X9_^^_0;W\^>W$3'_\+P>M(MHX/MQ_\!^B=@#S,8V`8-/B38Q@P-+CB##S-$.$,],[P080=MO(`AAR]TMD,,+/H3H@XV.#6##H888-MM)'GA#!TDB2'::),F*]J=(QUXWVBCWG>SJ"*0/YKX#]MMMF]C!AR]8V.2!$';-8(%7)T:YP%/GY1!QR$+"PJORP>0HY)-63Y)2MK'L:)5A;L6=2IN5/^Y%+H%7ABD'JU*NL',1;+M$?62F'#S)&)99SK98LYT/@\YM&$D)JC)2D>1UR6+RH(>597T/6;-$G[1*C:W[Z0_EM=K`?_R1F/W'4VH$ZTC5L#NJ0@_38(
